Individualized Prophylaxis for Severe Hemophilia A Children

NCT02116855 | Unknown

• 1 other identifier: BCH-20140415
• Study Type: interventional
• Target: 50
• Locations: 0 countries
• Sites: N/A

Brief Summary

A multi centre two year long term escalating dose tertiary prophylaxis study on the efficacy and cost saving of individualized low dose prophylaxis regimens for boys with severe hemophilia A in China staring with a low dose regimen in step I, an escalated low dose regimen in step II and a tailored dose regimen based on individual PK profiles in step III. The dose escalation criteria are adjusted according to patterns and frequencies of joint bleeding and assessed in each subject every 3 months. Efficacy of the 3 different dose regimens are measured by the Annualized Joint Bleeding rate (AJBR) as a primary end point and the Hemophilia Joint Health Score (HJHS ) and QoL scores (CHO-KLAT and PedsQoL) , image studies of target joints by Ultrasound, X-ray and MRI examinations, consumption of factor VIII and inhibitor rates as secondary end points.

Conditions

Hemophilia

Outcome Measures

Primary Outcomes (1)

• AJBRs (annualized Joint bleeding rates)

  three months

Study Arms (1)

tertiary prophylaxis prophy on Hemophilia A patiets

EXPERIMENTAL

A multi centre 2 year long term tertiary prophylaxis study designed with a three step escalating dose protocol adjusted by individual joint bleeding patterns/frequencies to study the effect and cost saving of 3 low dose /cost prophylaxis regimens in boys with severe hemophilia A and arthropathy in China. Each patient will start treatment with a low dose regimen in step I and be assessed every 3 months according to the escalating criteria.

Other: according to the efficacy of AJBRs

Interventions

according to the efficacy of AJBRs OTHER

tertiary prophylaxis prophy on Hemophilia A patiets

Eligibility Criteria

• Age: 6 Years - 10 Years
• Sex: male
• Healthy Volunteers: No
• Age Groups: Child (0-17)

You may qualify if:

• Severe hemophilia A with FVIII \<1 %
• Age from 6 to 10 years
• Patients with more than 50 exposure day (ED)
• Patients with one or more target joints (a target joint is defined as a joint with 3 or more bleeds in a consecutive 3 months) or disease joints (defined as presence of visible joint swelling and /or limitation of movements and/or joint deformities in the absent of an acute joint bleed )
• on-demand treatment more than 12months before the study

You may not qualify if:

• A history of FVIII inhibitor (titer greater than 0.6 BU) and detectable FVIII inhibitor at screening (titer greater than 0.6 BU)
• Chronic renal failure (serum creatinine greater than 2.0 mg /dL)
• Chronic Liver disease (ALT greater than 200 U/L))
• Patients with clinically documented immunodeficiencies
• Patients anticipated to require Major surgery
• Patients with competing high risks such as symptomatic HIV infection, Juvenile rheumatoid arthritis, metabolic bone diseases, or other diseases known to mimic or cause joint diseases
• Patients live too far from the comprehensive care centre at BCH and had demonstrated previous non compliance to therapies or clinical studies

Sponsors & Collaborators

• Beijing Children's Hospital: lead

MeSH Terms

Conditions

Hemophilia A

Condition Hierarchy (Ancestors)

Blood Coagulation Disorders, Inherited; Blood Coagulation Disorders; Hematologic Diseases; Hemic and Lymphatic Diseases; Coagulation Protein Disorders; Hemorrhagic Disorders; Genetic Diseases, Inborn; Congenital, Hereditary, and Neonatal Diseases and Abnormalities

Study Officials

• hui R Wu, MD

  Beijing Children's Hospital

  STUDY CHAIR

Central Study Contacts

Hui R Wu, MD

CONTACT

8613911383480; runhuiwu@hotmail.com

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: NA
• Masking: SINGLE
• Who Masked: OUTCOMES ASSESSOR
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Deputy Director of Hematology-Oncology Center

Study Record Dates

• First Submitted: April 15, 2014
• First Posted: April 17, 2014
• Study Start: June 1, 2014
• Primary Completion: June 1, 2016
• Last Updated: April 17, 2014

Record last verified: 2014-04